P340 Practice considerations in offering peanut oral immunotherapy (OIT) in the U.S.

Peanut allergy is a major health burden in the U.S. While POIT is not currently recommended in major guidelines nor is there an FDA-approved product, numerous practices offer it. This study was conducted to examine practice considerations for POIT.

http://ift.tt/2iHS1KR